CytomX Therapeutics, Inc. (CTMX) - Q1 2026 Filing Summary
Business Context and Reporting Period
CytomX Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company developing conditionally activated biologics using its proprietary PROBODY® platform. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is currently advancing two primary clinical programs: Varseta-M (an antibody-drug conjugate targeting EpCAM) and CX-801 (a masked interferon-alpha-2b).
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $10,258 | $50,917 |
| Net Loss | $(18,248) | $23,525 (Income) |
| Operating Expenses | $29,930 | $28,296 |
| Cash, Cash Equivalents & Short-Term Investments | $346,707 | $137,052 |
| Accumulated Deficit | $(730,197) | $(668,054) |
| Net Cash Used in Operating Activities | $(25,549) | $(21,043) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately $40.7 million (80%) compared to Q1 2025. This was primarily due to the completion of performance obligations under the Bristol Myers Squibb (BMS) agreement and the termination of the Amgen EGFR product license in Q1 2025, which accelerated revenue recognition in the prior year.
- Profitability Shift: The company reported a net loss of $18.2 million in Q1 2026, compared to net income of $23.5 million in Q1 2025. The prior year's income was significantly boosted by milestone payments and accelerated revenue recognition from collaboration terminations.
- Liquidity Increase: Cash and short-term investments increased from $137.1 million to $346.7 million. This was driven by a March 2026 underwritten public offering that raised approximately $234.2 million in net proceeds.
- Expense Management: Research and Development (R&D) expenses increased slightly by $0.4 million, driven by higher external costs for Varseta-M ($3.5 million increase), partially offset by a $2.3 million decrease in internal costs due to the absence of restructuring expenses incurred in Q1 2025.
Guidance, Outlook, and Risks
- Clinical Progress:
- Varseta-M: Phase 1 dose expansion data (as of Jan 16, 2026) showed a confirmed overall response rate (cORR) of 32% at the 10 mg/kg dose and 20% at 8.6 mg/kg in late-line metastatic colorectal cancer (CRC). Dose optimization is complete, and the company plans to initiate a Phase 1/2 combination study with bevacizumab, 5-FU, and leucovorin in H2 2026. A registrational study is targeted for H1 2027.
- CX-801: Phase 1 dose escalation in melanoma is ongoing. Combination studies with KEYTRUDA® (pembrolizumab) are enrolling. Data from the combination arm is expected by the end of 2026.
- Liquidity Outlook: Management expects existing capital resources to fund operations into at least the second half of 2028.
- Collaboration Updates:
- Astellas: Terminated the agreement effective May 12, 2026. This triggered a $7.1 million revenue recognition in Q1 2026.
- Moderna: Activities remain paused pending budget alignment.
- Risks: Key risks include the uncertainty of clinical trial outcomes, potential delays in patient enrollment, reliance on third-party manufacturers (including in China), and the need for additional capital to sustain operations beyond 2028. The company also faces regulatory risks regarding the BIOSECURE Act and potential trade restrictions.
Investor Verification Checklist
- Verify the sustainability of the $234.2 million cash raise and the specific terms of the March 2026 offering.
- Monitor the timeline for the initiation of the Varseta-M combination study with bevacizumab in H2 2026.
- Assess the impact of the Astellas termination on future deferred revenue recognition and the timeline for the remaining $18.9 million in deferred revenue.
- Review the safety profile of Varseta-M, specifically regarding the previously reported Grade 5 acute kidney injury and the efficacy of the updated prophylactic regimen for diarrhea.
- Confirm the status of the Moderna collaboration and the likelihood of resuming activities.